In collaboration between NCITA and the ReIMAGINE consortium, the PROMIS Study Dataset has been made openly and freely available to the scientific community for non-commercial, non-profit use, in the hope of facilitating future advancement and discovery in prostate cancer diagnosis and treatment.
The “PROMIS – Prostate MRI Imaging Study – Evaluation of multiparametric magnetic resonance imaging in the diagnosis and characterisation of prostate cancer” study was a prospective, multi-centre, paired-cohort, confirmatory study that tested the value of multi parametric Magnetic Resonance Imaging (mp-MRI) for men with a suspicion of prostate cancer who had been recommended to have a prostate biopsy. Participants in the study underwent both a template prostate mapping biopsy and a trans-rectal ultrasound biopsy as a combined procedure after MRI, regardless of MRI outcome (a 5-point Likert radiology reporting scale was used).
The PROMIS results were published in the Lancet in January 2017, and demonstrated that trans-rectal ultrasound biopsy is a poor test for diagnosis of clinically significant prostate cancer, with a sensitivity of only 48%, whereas mp-MRI is a highly sensitive test (93%) and if performed prior to the biopsy, it can identify about 25% of men who might safely avoid a biopsy. A subsequent cost effectiveness analysis demonstrated that performing an mp-MRI scan prior to biopsy was highly cost effective.
The PROMIS study dataset and the biobank is under the research governance of the ReIMAGINE Risk Trial Management Group, in collaboration with NCITA.
The PROMIS study dataset includes:
- 575 participant’s mpMRI DICOMs files (.dcm)
- 575 MRI study report forms (PDF)
- 575 TPM study report forms (PDF)
- 22 study database download spreadsheets (.xlsx)